Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.42 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | KLKB1 | P03952 | 4/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 1/20 | 0.37 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21089856 | 0.92 | TAS2R8 (0.40) | TAS2R8PRMT5WDR77SCDKLKB1 | |
| SCHEMBL21049881 | 0.89 | KLKB1 (0.42) | TAS2R8KLKB1FFAR1DGAT1ANPEP | |
| SCHEMBL21049915 | 0.87 | SCD (0.42) | PRMT5WDR77SCDFFAR1AAK1 | |
| SCHEMBL17129343 | 0.83 | AAK1 (0.53) | PRMT5WDR77AAK1BRD4DGAT1 | |
| SCHEMBL21049887 | 0.82 | KLKB1 (0.42) | TAS2R8KLKB1FFAR1ANPEPGLS | |
| SCHEMBL21049901 | 0.81 | MEN1 (0.44) | TAS2R8KLKB1FFAR1DGAT1 | |
| SCHEMBL14858471 | 0.81 | DGAT1 (0.52) | KLKB1FFAR1DGAT1ANPEP | |
| SCHEMBL29801489 | 0.81 | DGAT1 (0.52) | KLKB1FFAR1DGAT1ANPEP | |
| SCHEMBL13737592 | 0.80 | SCD (0.50) | PRMT5WDR77SCDKLKB1FFAR1 | |
| SCHEMBL28632622 | 0.79 | APP (0.42) | KLKB1FFAR1DGAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10577383-B2 | Macrocyclic inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190177340-A1 | MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177340-A1 | MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | TAS2R8 4808/4885PRMT5 493/4885WDR77 2006/4885 |
| US-10577383-B2 | Macrocyclic inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | TAS2R8 4808/4885PRMT5 493/4885WDR77 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.